CBD and Medications – Interactions You Need to Know

Cannabidiol (CBD) is generally considered a well-tolerated substance with a favorable safety profile. However, this description can create a false sense of security. CBD is a pharmacologically active compound that enters the same metabolic pathways as hundreds of commonly prescribed drugs. The result can be clinically significant interactions – ranging from dangerous elevation of drug levels in the blood to a drop below the therapeutic threshold.

Cannapio seedsOur own brandBrowse ›Tip for this articleAuto Banana OG Kush - autoflowering seeds 5 pcs Cannapio€19.30Browse ›Tip for this articleAuto Pure Haze - 3pcs Cannapio Autoflowering Seeds€9.20Browse ›

This article is intended for anyone who uses or is considering using CBD oil or other CBD products simultaneously with prescription medications or over-the-counter medicines. It does not replace a consultation with a doctor – but it will help you ask the right questions and recognize situations where caution is essential.

How CBD Affects Drug Metabolism: The CYP450 System

What is Cytochrome P450

Cytochrome P450 (CYP450) is a family of enzymes concentrated mainly in the liver, which ensures metabolism – the conversion and breakdown – of approximately 60–80% of all clinically used medications. Once you swallow a tablet, CYP450 enzymes biochemically process it and prepare it for elimination from the body. Disruption of their activity can therefore have far-reaching consequences for the efficacy and safety of treatment.

Among the most important enzymes in this system are:

• CYP3A4 – metabolizes approximately 25% of all drugs
• CYP2D6 – metabolizes approximately 25% of drugs, particularly psychotropic medications
• CYP2C9 – metabolizes warfarin, ibuprofen, and related substances
• CYP2C19 – metabolizes antidepressants and proton pump inhibitors
• CYP1A2 – metabolizes caffeine, theophylline, and some antipsychotics

How CBD Interacts with CYP450

CBD is a potent inhibitor of several key CYP450 enzymes. A systematic review published in Drug Metabolism Reviews (2024) confirmed that CBD:

• Is a potent inhibitor of CYP3A4 – the enzyme that metabolizes one-quarter of all drugs.
• Is a potent inhibitor of CYP2D6 – an enzyme essential for the metabolism of antidepressants, antipsychotics, and opioids.
• Inhibits CYP2C9, CYP2C19, and CYP2C8 – enzymes responsible for the metabolism of anticoagulants, anti-inflammatory drugs, and some anticonvulsants.
• Inhibits UGT2B7 and UGT1A9 – enzymes responsible for glucuronidation, the second phase of drug metabolism.
• Depending on the context, may induce or inhibit CYP1A2 and CYP2B6.

CBD itself is metabolized by the enzymes CYP3A4, CYP2C9, and CYP2C19.

What does this mean in practice? If CBD inhibits the enzyme that breaks down your medication, that drug is eliminated from your body more slowly, its level in the blood rises, and the risk of adverse effects increases – even with completely standard dosing. The opposite effect occurs with enzyme induction: the drug is broken down faster and its therapeutic efficacy decreases.

The Grapefruit Rule

Principle

Researchers from Penn State College of Medicine formulated a practical guide known as the "grapefruit rule." Grapefruit and some other citrus fruits contain furanocoumarins, which inhibit CYP3A4 in a manner similar to CBD.

Practical conclusion: If your medication carries a warning not to combine it with grapefruit juice, it very likely interacts with CBD as well.

The Penn State team identified more than 85 drugs that interact with grapefruit, of which 57 can lead to serious or fatal complications through changes in blood concentration. Researchers also developed an online tool called CANN-DIR (Cannabinoid Drug Interaction Review), available at cann-dir.psu.edu, which allows you to systematically search for potential CBD interactions with specific medications.

Limitations of the Grapefruit Rule

The grapefruit rule serves as initial guidance but has significant limitations:

• CBD inhibits enzymes that grapefruit does not affect – particularly CYP2D6 and CYP2C9.
• The severity of inhibition depends on the CBD dose and the patient's individual genetic makeup (CYP450 enzyme polymorphisms).
• The rule cannot be used as the sole source of information – always consult a doctor or pharmacist.

Specific Drug Categories and Their Interactions with CBD

Anticoagulants (Blood Thinners)

Warfarin represents one of the most documented and potentially most dangerous interactions with CBD. A case report published in Epilepsy & Behavior Case Reports described a 44-year-old man with Marfan syndrome and a mechanical mitral valve replacement:

• Gradual dose increases of CBD (Epidiolex) led to a nonlinear increase in INR (International Normalized Ratio – a measure of blood coagulation).
• The warfarin dose had to be reduced by approximately 30%.

A 2023 systematic review published in Pharmacotherapy analyzed seven case reports:

• In six of seven cases, INR increased.
• Maximum recorded INR changes ranged from +0.4 to +9.61 – with values above 4.0 significantly increasing the risk of uncontrolled bleeding.

Mechanism: Both CBD and THC are moderate-to-potent inhibitors of CYP2C9, which metabolizes the pharmacologically more active S-warfarin. Inhibition of this enzyme slows warfarin breakdown, increases its blood level, and strengthens the anticoagulant effect.

Risk: High. Uncontrolled increase in warfarin's anticoagulant effect can lead to serious or life-threatening bleeding.

Anticonvulsants

An apparent paradox: CBD is a registered medication for epilepsy (Epidiolex), yet it interacts with other anticonvulsants in a clinically relevant way:

The interactions between CBD and clobazam and valproic acid are best documented, as they appeared directly in Epidiolex's regulatory clinical trials. The EFSA in its 2025 statement explicitly states that CBD can worsen hepatotoxicity when used concurrently with valproic acid.

Antidepressants and Anxiolytics

CBD inhibits CYP2D6 and CYP2C19, and these very enzymes metabolize a large portion of commonly prescribed antidepressants:

A clinical trial with bupropion showed that CBD increases its plasma levels. A similar interaction has been documented with citalopram, where changes reached clinical relevance.

Immunosuppressants

CBD interactions with immunosuppressants are among the most serious of all. A systematic review in Frontiers in Pharmacology (2024) analyzed five studies involving 35 patients treated with tacrolimus, everolimus, and sirolimus who were simultaneously using THC and/or CBD:

• In 46% of patients (16 of 35), adverse effects associated with drug toxicity developed.
• The mechanism involves CBD's inhibition of CYP3A4 – this enzyme is the primary metabolic pathway for all three mentioned immunosuppressants. The result is a marked elevation of their blood levels.

This interaction is particularly critical in organ transplant patients, where precise maintenance of the therapeutic window of immunosuppressants directly affects graft survival.

Cardiovascular Drugs

Analgesics (Pain Medications)

Opioids deserve special attention: with codeine and tramadol, CBD paradoxically reduces analgesic effect because it blocks their conversion to active opioid metabolites. With direct opioid agonists like fentanyl or oxycodone, CBD increases levels, raising the risk of respiratory depression and overdose.

Oncology Medications

A significant portion of anticancer drugs are metabolized by CYP3A4 and CYP2D6 enzymes. CBD can affect the levels of these drugs in a clinically relevant manner:

• Tamoxifen (breast cancer) – CYP2D6
• Imatinib and other tyrosine kinase inhibitors – CYP3A4
• Cyclophosphamide – CYP2B6, CYP3A4

In cancer patients, consultation with the treating oncologist before any CBD initiation is absolutely essential. Disruption of cytostatic pharmacokinetics can have a direct impact on treatment efficacy and safety profile.

Hepatotoxicity: The Liver as a Vulnerable Target

The EFSA identified hepatotoxicity as a key CBD safety concern in its 2025 statement. Available data are unequivocal:

• In clinical trials, healthy adults receiving CBD at approximately 5 mg/kg/day (300–400 mg/day) experienced ALT elevation above three times the upper limit of normal in 6–7% of participants.
• Most of these cases met diagnostic criteria for DILI (Drug-Induced Liver Injury).
• Combination of CBD with valproic acid significantly multiplies hepatotoxicity risk.
• In animal studies, liver changes were a consistent and reproducible finding across various models.

For daily CBD users, this implies specific recommendations:

1. With long-term use of higher doses (above 50 mg/day), consider regular liver function testing (ALT, AST, GGT).
2. With any history of liver disease, consult a hepatologist before starting CBD.
3. With concurrent use of liver-metabolized drugs, hepatotoxicity risk cumulates – it cannot be assessed in isolation. For more details on safety limits, see the article EFSA and Safe Daily CBD Intake.

Practical Guide: When and How to Consult Your Doctor

Always consult your doctor if:

• You take any prescription medications – especially from the categories mentioned above.
• Your medication carries a warning about interaction with grapefruit juice.
• You take anticoagulants (warfarin, heparin, new oral anticoagulants like rivaroxaban or apixaban).
• You take anticonvulsants of any kind.
• You are after organ transplant or use immunosuppressants for another reason.
• You have liver disease or persistently elevated liver enzymes.
• You are pregnant or breastfeeding.
• You are under 25 years old (the endocannabinoid system is still developing until this age).

What to Tell Your Doctor

Many doctors still lack direct clinical experience with CBD. For an effective consultation, prepare in advance:

1. Product type – full spectrum, broad spectrum, or isolate; form (oil, capsule, other).
2. Exact CBD dose in milligrams – not in drops, as concentration varies product to product.
3. Frequency of use – once daily, twice daily, as needed.
4. Reason for use – which health problem you are using or planning to use CBD for.
5. Link to the CANN-DIR database (cann-dir.psu.edu) – Penn State University's tool for systematic cannabinoid drug interaction searches, which your doctor can use directly during consultation.

Recommended Measures When Taking Medications and CBD Concurrently

Factors Affecting the Severity of Interactions

Not every CBD-drug interaction is clinically significant. The actual severity depends on a combination of multiple variables:

CBD Dose

Most clinically documented interactions appeared at doses of 5–20 mg/kg/day (350–1400 mg/day) – that is, at pharmaceutical doses of the registered product Epidiolex. Common consumer doses in the range of 10–50 mg/day likely pose lower, but not zero, risk. CBD's inhibitory potential on CYP enzymes is apparent even at lower concentrations, just to a lesser degree.

Type of CBD Product

• Full spectrum products contain, besides CBD, also THC, terpenes, and other cannabinoids, each with its own interaction potential toward CYP450.
• CBD isolate provides a cleaner interaction profile, but inhibition of CYP enzymes by CBD itself persists.

Patient's Genetic Makeup

Polymorphisms in genes encoding CYP450 enzymes cause the population to divide into "poor metabolizers" and "extensive metabolizers." Poor metabolizers are more prone to drug and CBD accumulation and their mutual interactions – without knowing it.

Age and Liver Function Status

Older individuals and patients with impaired liver function metabolize both CBD and concurrently used drugs more slowly. This increases the risk of accumulation and intensifies interactions. CBD dosing must be adjusted individually in these groups.

Frequently Asked Questions (FAQ)

Can I take CBD with acetaminophen?

Acetaminophen is metabolized partially by CYP1A2 and CYP2E1 enzymes. CBD may theoretically affect its metabolism, but clinically significant interaction at common doses of both substances has not yet been reliably proven. However, increased caution is warranted in those with liver disease: both acetaminophen and CBD can be hepatotoxic with impaired liver function, and their combination increases this risk.

Is CBD safe when taking antidepressants?

It depends on the specific drug. CBD inhibits CYP2D6 and CYP2C19, which are the primary metabolic pathways for most SSRIs and SNRIs. Consult with your psychiatrist before starting CBD. Never stop or change your antidepressant dose on your own – sudden discontinuation can trigger withdrawal syndrome and mental health destabilization.

Does CBD interact with hormonal contraception?

Ethinylestradiol and levonorgestrel in combined contraceptives are metabolized by CYP3A4. CBD may theoretically increase their plasma levels, but clinical evidence for this interaction at consumer CBD doses is still limited. For individual assessment, consult your gynecologist.

Can I combine CBD with blood pressure medications?

Calcium channel blockers (amlodipine, diltiazem, verapamil) and beta-blockers (metoprolol, propranolol) are metabolized by enzymes that CBD inhibits. The combination may lead to deepened hypotension or bradycardia. Always discuss this question with your cardiologist, ideally before starting CBD.

How long before surgery should I stop taking CBD?

Given potential interactions with anesthetics and anticoagulants, it is generally recommended to stop CBD at least 1–2 weeks before scheduled surgery. Remember to inform your anesthesiologist that you have been using CBD – this information is relevant to the choice and dosing of anesthesia.

Where can I find a complete overview of CBD-drug interactions?

Penn State University operates a publicly available database called CANN-DIR (cann-dir.psu.edu), which allows you to systematically search for potential interactions between CBD and THC and specific drugs. The database is continuously updated based on the latest research data and can serve as a basis for consultation with your doctor.

Conclusion

CBD is not a dangerous poison – but it is also not a pharmacologically inert herbal supplement. It is a biologically active compound that fundamentally affects the metabolism of many drugs through the cytochrome P450 system. With specific drug classes – anticoagulants, anticonvulsants, and immunosuppressants – this interaction can be clinically very serious and potentially life-threatening.

The key message is simple: if you take any prescription medications, consult your doctor before starting CBD. The grapefruit rule is a useful initial guide but does not replace individual expert assessment. If you decide to use CBD, choose products from transparent manufacturers with documented composition – our CBD oil comparison can help you navigate the market.

Sources

1. Harvard Health. (2021). CBD and other medications: Proceed with caution. Harvard Health
2. Effects of cannabidiol and delta-9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. (2024). Drug Metabolism Reviews, 56(2). Taylor & Francis
3. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. (2024). Frontiers in Pharmacology. Frontiers
4. CANN-DIR: Cannabinoid Drug Interaction Review. Penn State University. CANN-DIR
5. An interaction between warfarin and cannabidiol, a case report. (2018). PMC. PMC
6. Anticoagulant drug-drug interactions with cannabinoids: A systematic review. (2023). Pharmacotherapy. Wiley
7. Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review. (2021). PMC. PMC
8. Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice. (2024). PMC. PMC
9. EFSA. (2025). Provisional safe level for cannabidiol as a novel food. EFSA
10. EFSA. (2022). Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA